-
Multiple imputation of partially observed data after treatment-withdrawal
Authors:
Suzie Cro,
James H Roger,
James R Carpenter
Abstract:
The ICH E9(R1) Addendum (International Council for Harmonization 2019) suggests treatment-policy as one of several strategies for addressing intercurrent events such as treatment withdrawal when defining an estimand. This strategy requires the monitoring of patients and collection of primary outcome data following termination of randomized treatment. However, when patients withdraw from a study be…
▽ More
The ICH E9(R1) Addendum (International Council for Harmonization 2019) suggests treatment-policy as one of several strategies for addressing intercurrent events such as treatment withdrawal when defining an estimand. This strategy requires the monitoring of patients and collection of primary outcome data following termination of randomized treatment. However, when patients withdraw from a study before nominal completion this creates true missing data complicating the analysis. One possible way forward uses multiple imputation to replace the missing data based on a model for outcome on and off treatment prior to study withdrawal, often referred to as retrieved dropout multiple imputation. This article explores a novel approach to parameterizing this imputation model so that those parameters which may be difficult to estimate have mildly informative Bayesian priors applied during the imputation stage. A core reference-based model is combined with a compliance model, using both on- and off- treatment data to form an extended model for the purposes of imputation. This alleviates the problem of specifying a complex set of analysis rules to accommodate situations where parameters which influence the estimated value are not estimable or are poorly estimated, leading to unrealistically large standard errors in the resulting analysis.
△ Less
Submitted 25 August, 2023;
originally announced August 2023.
-
Improving clinical trial interpretation with ACCEPT analyses
Authors:
Michelle N. Clements,
Ian R. White,
Andrew J. Copas,
Victoria Cornelius,
Suzie Cro,
David T Dunn,
Matteo Quartagno,
Rebecca M. Turner,
Conor D. Tweed,
A. Sarah Walker
Abstract:
Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical trials can cause confusion both in trial design and in comparing results across trials. ACceptability Curve Estimation using Probability Above Threshold (ACCEPT) aids comparison between trials (even where of different desig…
▽ More
Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical trials can cause confusion both in trial design and in comparing results across trials. ACceptability Curve Estimation using Probability Above Threshold (ACCEPT) aids comparison between trials (even where of different designs) by harmonising reporting of results, acknowledging different interpretations of the results may be valid in different situations, and moving the focus from comparison to a pre-specified value to interpretation of the trial data. ACCEPT can be applied to historical trials or incorporated into statistical analysis plans for future analyses. An online tool enables ACCEPT on up to three trials simultaneously.
△ Less
Submitted 15 June, 2022; v1 submitted 21 March, 2022;
originally announced March 2022.
-
Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
Authors:
Kelly Van Lancker,
Sergey Tarima,
Jonathan Bartlett,
Madeline Bauer,
Bharani Bharani-Dharan,
Frank Bretz,
Nancy Flournoy,
Hege Michiels,
Camila Olarte Parra,
James L Rosenberger,
Suzie Cro
Abstract:
The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as site closures, travel limitations and interruptions to the supply chain for the investigational product, or from health-related challenges such as COVID-19 infections. Some of these complications lead to unforeseen intercurrent events in th…
▽ More
The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as site closures, travel limitations and interruptions to the supply chain for the investigational product, or from health-related challenges such as COVID-19 infections. Some of these complications lead to unforeseen intercurrent events in the sense that they affect either the interpretation or the existence of the measurements associated with the clinical question of interest. In this article, we demonstrate how the ICH E9(R1) Addendum on estimands and sensitivity analyses provides a rigorous basis to discuss potential pandemic-related trial disruptions and to embed these disruptions in the context of study objectives and design elements. We introduce several hypothetical estimand strategies and review various causal inference and missing data methods, as well as a statistical method that combines unbiased and possibly biased estimators for estimation. To illustrate, we describe the features of a stylized trial, and how it may have been impacted by the pandemic. This stylized trial will then be re-visited by discussing the changes to the estimand and the estimator to account for pandemic disruptions. Finally, we outline considerations for designing future trials in the context of unforeseen disruptions.
△ Less
Submitted 7 February, 2022;
originally announced February 2022.
-
How to design a pre-specified statistical analysis approach to limit p-hacking in clinical trials: the Pre-SPEC framework
Authors:
Brennan C Kahan,
Gordon Forbes,
Suzie Cro
Abstract:
Results from clinical trials can be susceptible to bias if investigators choose their analysis approach after seeing trial data, as this can allow them to perform multiple analyses and then choose the method that provides the most favourable result (commonly referred to as 'p-hacking'). Pre-specification of the planned analysis approach is essential to help reduce such bias, as it ensures analytic…
▽ More
Results from clinical trials can be susceptible to bias if investigators choose their analysis approach after seeing trial data, as this can allow them to perform multiple analyses and then choose the method that provides the most favourable result (commonly referred to as 'p-hacking'). Pre-specification of the planned analysis approach is essential to help reduce such bias, as it ensures analytical methods are chosen in advance of seeing the trial data. However, pre-specification is only effective if done in a way that does not allow p-hacking. For example, investigators may pre-specify a certain statistical method such as multiple imputation, but give little detail on how it will be implemented. Because there are many different ways to perform multiple imputation, this approach to pre-specification is ineffective, as it still allows investigators to analyse the data in different ways before deciding on a final approach. In this article we describe a five-point framework (the Pre-SPEC framework) for designing a pre-specified analysis approach that does not allow p-hacking. This framework is intended to be used in conjunction with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement and other similar guidelines to help investigators design the statistical analysis strategy for the trial's primary outcome in the trial protocol.
△ Less
Submitted 16 July, 2020; v1 submitted 9 July, 2019;
originally announced July 2019.
-
Information-Anchored Sensitivity Analysis: Theory and Application
Authors:
Suzie Cro,
James R Carpenter,
Michael G Kenward
Abstract:
Analysis of longitudinal randomised controlled trials is frequently complicated because patients deviate from the protocol. Where such deviations are relevant for the estimand, we are typically required to make an untestable assumption about post-deviation behaviour in order to perform our primary analysis and estimate the treatment effect. In such settings, it is now widely recognised that we sho…
▽ More
Analysis of longitudinal randomised controlled trials is frequently complicated because patients deviate from the protocol. Where such deviations are relevant for the estimand, we are typically required to make an untestable assumption about post-deviation behaviour in order to perform our primary analysis and estimate the treatment effect. In such settings, it is now widely recognised that we should follow this with sensitivity analyses to explore the robustness of our inferences to alternative assumptions about post-deviation behaviour. Although there has been a lot of work on how to conduct such sensitivity analyses, little attention has been given to the appropriate loss of information due to missing data within sensitivity analysis. We argue more attention needs to be given to this issue, showing it is quite possible for sensitivity analysis to decrease and increase the information about the treatment effect. To address this critical issue, we introduce the concept of information-anchored sensitivity analysis. By this we mean sensitivity analysis in which the proportion of information about the treatment estimate lost due to missing data is the same as the proportion of information about the treatment estimate lost due to missing data in the primary analysis. We argue this forms a transparent, practical starting point for interpretation of sensitivity analysis. We then derive results showing that, for longitudinal continuous data, a broad class of controlled and reference-based sensitivity analyses performed by multiple imputation are information-anchored. We illustrate the theory with simulations and an analysis of a peer review trial, then discuss our work in the context of other recent work in this area. Our results give a theoretical basis for the use of controlled multiple imputation procedures for sensitivity analysis.
△ Less
Submitted 15 May, 2018;
originally announced May 2018.
